Last reviewed · How we verify
NCT03541577: SUPREME
Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for FFR Measurement
trial testing TruePhysioTM Microcatheter in Coronary Artery Disease in 242 participants. Completed in 31 January 2019.
31 January 2019
Quick facts
| Lead sponsor | Insight Lifetech Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 242 |
| Start date | 19 June 2018 |
| Primary completion | 31 January 2019 |
| Estimated completion | 31 January 2019 |
| Sites | 4 locations across China |
Drugs / interventions tested
- TruePhysioTM Microcatheter
- Pressure Wire
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Coronary Disease — all drugs for Coronary Disease →
- Myocardial Ischemia — all drugs for Myocardial Ischemia →
Sponsor
Insight Lifetech Co., Ltd.
Who can join
Adults 18 to 75, any sex, with Coronary Artery Disease or Coronary Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TruePhysioTM Sensor-equipped Ultrathin Pressure Microcatheter (referred to as TruePhysioTM Microcatheter below) is a novel device for evaluating the functional significance of coronary stenosis. This study will compare the differences, if any, between the coronary fractional flow reserve (FFR) measured by the TruePhysioTM Microcatheter and the Pressure Wire.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03541577
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Insight Lifetech Co., Ltd. trials
Trials by the same sponsor.
- NCT07176585 — A Prospective, Single-site, Single-group Value Study on the Diagnosis of Functional Myocardial Ischemia Based on IVUS Pl · completed
- NCT06030271 — A Prospective, Non-Randomized Pivotal Clinical Investigation to Demonstrate the Safety and Performance of the TrueCross · NA · completed
- NCT05417763 — Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for Physiological Measurements · completed
- NCT04739657 — Clinical Evaluation of A New High-speed and High-resolution Intravascular Ultrasound System · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03541577 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insight Lifetech Co., Ltd.
- Last refreshed: 27 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541577.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing